Lexaria Bioscience Corp. Signs Material Definitive Agreement

TL;DR

Lexaria Bioscience Corp. signed a big deal on Aug 21st. Details TBD.

AI Summary

Lexaria Bioscience Corp. announced on August 21, 2024, that it has entered into a material definitive agreement. The company, incorporated in Nevada, filed an 8-K report detailing this agreement. Further specifics regarding the nature of the agreement and any associated financial figures are not detailed in this initial filing.

Why It Matters

This filing indicates a significant business development for Lexaria Bioscience Corp., potentially impacting its future operations and strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but lacks specific details to fully assess the risk.

Key Players & Entities

• Lexaria Bioscience Corp. (company) — Registrant
• August 21, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
• $20,000,000 — ssue and sell, from time to time, up to $20,000,000 in aggregate principal amount of shares

Filing Documents

• lxrp_8k.htm (8-K) — 32KB
• lxrp_ex11.htm (EX-1.1) — 240KB
• lxrp_ex51.htm (EX-5.1) — 14KB
• lxrp_ex51img1.jpg (GRAPHIC) — 6KB
• lxrp_ex51img2.jpg (GRAPHIC) — 6KB
• 0001640334-24-001346.txt ( ) — 502KB
• lxrp-20240821.xsd (EX-101.SCH) — 6KB
• lxrp-20240821_lab.xml (EX-101.LAB) — 16KB
• lxrp-20240821_cal.xml (EX-101.CAL) — 1KB
• lxrp-20240821_pre.xml (EX-101.PRE) — 12KB
• lxrp-20240821_def.xml (EX-101.DEF) — 4KB
• lxrp_8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2024, Lexaria Bioscience Corp. (the "Company") entered into a Capital on Demand Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC (the "Agent"), pursuant to which the Company may issue and sell, from time to time, up to $20,000,000 in aggregate principal amount of shares (the "Shares") of the Company's common stock, par value $0.001 per share, through or to the Agent, as the Company's sales agent or principal. Any Shares to be offered and sold under the Sales Agreement will be issued and sold by methods deemed to be an "at-the-market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Act"), or in negotiated transactions, if authorized by the Company. The offering of the Shares will terminate upon the earliest of (a) the issuance and sale of all of the Shares by the Agent on the terms and subject to the conditions set forth in the Sales Agreement or (b) the termination of the Sales Agreement by either of the parties thereto. The sale of Shares, i

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 Capital on Demand Sales Agreement, dated as of August 21, 2024, by and between Lexaria Bioscience Corp. and JonesTrading Institutional Services LLC 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 23.1 Consent of Sichenzia Ross Ference Carmel LLP (contained in the opinion filed as Exhibit 5.1 hereto) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 22, 2024 LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Name: Chris Bunka Title: Chief Executive Officer 4